- Home
- KALA vs PMCB Comparison
KALA vs PMCB Comparison
Compare KALA & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- PMCB
- Stock Information
- Founded
- KALA 2009
- PMCB 1996
- Country
- KALA United States
- PMCB United States
- Employees
- KALA N/A
- PMCB N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KALA Health Care
- PMCB Health Care
- Exchange
- KALA Nasdaq
- PMCB Nasdaq
- Market Cap
- KALA 28.2M
- PMCB 15.8M
- IPO Year
- KALA 2017
- PMCB N/A
- Fundamental
- Price
- KALA $6.00
- PMCB $1.59
- Analyst Decision
- KALA Strong Buy
- PMCB
- Analyst Count
- KALA 2
- PMCB 0
- Target Price
- KALA $16.50
- PMCB N/A
- AVG Volume (30 Days)
- KALA 8.4K
- PMCB 15.4K
- Earning Date
- KALA 08-06-2024
- PMCB 09-16-2024
- Dividend Yield
- KALA N/A
- PMCB N/A
- EPS Growth
- KALA N/A
- PMCB N/A
- EPS
- KALA N/A
- PMCB N/A
- Revenue
- KALA N/A
- PMCB N/A
- Revenue This Year
- KALA N/A
- PMCB N/A
- Revenue Next Year
- KALA N/A
- PMCB N/A
- P/E Ratio
- KALA N/A
- PMCB N/A
- Revenue Growth
- KALA N/A
- PMCB N/A
- 52 Week Low
- KALA $4.21
- PMCB $1.39
- 52 Week High
- KALA $11.81
- PMCB $2.63
- Technical
- Relative Strength Index (RSI)
- KALA 46.60
- PMCB 40.34
- Support Level
- KALA $5.84
- PMCB $1.47
- Resistance Level
- KALA $6.14
- PMCB $1.61
- Average True Range (ATR)
- KALA 0.24
- PMCB 0.12
- MACD
- KALA 0.02
- PMCB -0.00
- Stochastic Oscillator
- KALA 36.23
- PMCB 39.22
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.